Page 154 - 南京医科大学学报自然科学版
P. 154
第41卷第2期
·304 · 南 京 医 科 大 学 学 报 2021年2月
cose oxidation in genetically diverse human glioblasto⁃ ture,2009,462(7274):739-744
mas in the mouse brain in vivo[J]. Cell Metab,2012,15 [40] PRABHU A,SARCAR B,KAHALI S,et al. Cysteine ca⁃
(6):827-837 tabolism:a novel metabolic pathway contributing to glio⁃
[27] SHIBAO S,MINAMI N,KOIKE N,et al. Metabolic het⁃ blastoma growth[J]. Cancer Res,2014,74(3):787-796
erogeneity and plasticity of glioma stem cells in a mouse [41] GAO P,YANG C,NESVICK C L,et al. Hypotaurine
glioblastoma model[J]. Neuro Oncol,2018,20(3):343- evokes a malignant phenotype in glioma through aber⁃
354 rant hypoxic signaling[J]. Oncotarget,2016,7(12):
[28] MAHER E A,MARIN⁃VALENCIA I,BACHOO R M,et 15200-15214
al. Metabolism of[U⁃13 C]glucose in human brain tu⁃ [42] YU D,XUAN Q,ZHANG C,et al. Metabolic alterations
mors in vivo[J]. NMR Biomed,2012,25(11):1234- related to glioma grading based on metabolomics and lip⁃
1244 idomics analyses[J]. Metabolites,2020,10(12):E478
[29] MASHIMO T,PICHUMANI K,VEMIREDDY V,et al. [43] 李 珊,李文斌. 25 例成人丘脑恶性神经胶质瘤临床
Acetate is a bioenergetic substrate for human glioblasto⁃ 特点分析[J]. 南京医科大学学报(自然科学版),2017,
ma and brain metastases[J]. Cell,2014,159(7):1603- 37(10):1320-1322,1326
1614 [44] NEFTEL C,LAFFY J,FILBIN M G,et al. An integrative
[30] GULARYAN S K,GULIN A A,ANUFRIEVA K S,et al. model of cellular states,plasticity,and genetics for glio⁃
Investigation of inter⁃ and intratumoral heterogeneity of blastoma[J]. Cell,2019,178(4):835-849
glioblastoma using TOF⁃SIMS[J]. Mol Cell Proteomics, [45] CUPERLOVIC⁃CULF M,FERGUSON D,CULF A,et al.
2020,19(6):960-970 1H NMR metabolomics analysis of glioblastoma sub⁃
[31] WANG X,YANG K,XIE Q,et al. Purine synthesis pro⁃ types:correlation between metabolomics and gene ex⁃
motes maintenance of brain tumor initiating cells in glio⁃ pression characteristics[J]. J Biol Chem,2012,287
ma[J]. Nat Neurosci,2017,20(5):661-673 (24):20164-20175
[32] WANG X,YANG K,WU Q,et al. Targeting pyrimidine [46] JIAPAER S,FURUTA T,TANAKA S,et al. Potential
synthesis accentuates molecular therapy response in strategies overcoming the temozolomide resistance for
glioblastoma stem cells[J]. Sci Transl Med,2019,11 glioblastoma[J]. Neurol Med Chir,2018,58(10):405-
(504):eaau4972 421
[33] ZHENG S,ALFARO⁃MUNOZ K,WEI W,et al. Prospec⁃ [47] DONG Q,HE L,CHEN L,et al. Opening the blood⁃brain
tive clinical sequencing of adult glioma[J]. Mol Cancer barrier and improving the efficacy of temozolomide treat⁃
Ther,2019,18(5):991-1000 ments of glioblastoma using pulsed,focused ultrasound
[34] BORODOVSKY A,SELTZER M J,RIGGINS G J. Al⁃ with a microbubble contrast agent[J]. Biomed Res Int,
tered cancer cell metabolism in gliomas with mutant 2018,2018:6501508
IDH1 or IDH2[J]. Curr Opin Oncol,2012,24(1):83-89 [48] ST⁃COEUR P⁃D,POITRAS J J,CUPERLOVIC⁃CULF
[35] ZHAO S,LIN Y,XU W,et al. Glioma⁃derived mutations M,et al. Investigating a signature of temozolomide resis⁃
in IDH1 dominantly inhibit IDH1 catalytic activity and tance in GBM cell lines using metabolomics[J]. J Neu⁃
induce HIF⁃1alpha[J]. Science,2009,324(5924):261- rooncol,2015,125(1):91-102
265 [49]SASAKI T,LOPES M B S,HANKINS G R,et al. Expres⁃
[36] TAMURA R,OHARA K,SASAKI H,et al. Histopatho⁃ sion of survivin,an inhibitor of apoptosis protein,in tu⁃
logical vascular investigation of the peritumoral brain mors of the nervous system[J]. Acta Neuropathol,2002,
zone of glioblastomas[J]. J Neurooncol,2018,136(2): 104(1):105-109
233-241 [50] HVINDEN I C,BERG H E,SACHSE D,et al. Nuclear
[37] CONTI NIBALI M,ROSSI M,SCIORTINO T,et al. Pre⁃ magnetic resonance spectroscopy to identify metabolite
operative surgical planning of glioma:limitations and re⁃ biomarkers of nonresponsiveness to targeted therapy in
liability of fMRI and DTI tractography[J]. J Neurosurg glioblastoma tumor stem cells[J]. J Proteome Res,2019,
Sci,2019,63(2):127-134 18(5):2012-2020
[38] CHEN L C,ZHANG H Y,QIN Z Y,et al. Serological [51] CHANDRA A,JAHANGIRI A,CHEN W,et al. Clonal
identification of URGCP as a potential biomarker for gli⁃ ZEB1 ⁃ driven mesenchymal transition promotes targeta⁃
oma[J]. CNS Neurosci Ther,2014,20(4):301-307 ble oncologic antiangiogenic therapy resistance[J]. Can⁃
[39] DANG L,WHITE D W,GROSS S,et al. Cancer⁃associat⁃ cer Res,2020,80(7):1498-1511
ed IDH1 mutations produce 2⁃hydroxyglutarate[J]. Na⁃ [52] PALANICHAMY K,THIRUMOORTHY K,KANJI S,et